Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
WP1220 · 1 trial · 1 indication
Safety will be evaluated by reported adverse events
| Arm | Type | Description |
|---|---|---|
| 10% WP1220 ointment | EXPERIMENTAL | 10% WP1220 ointment topically applied 2x day for 84 days |
| Name | Type | Description |
|---|---|---|
| WP1220 | DRUG | Topical administration 2x daily for 84 consecutive days |
Inclusion Criteria: 1. Age ≥ 18 years at the time of signing informed consent. 2. Clinical diagnosis of MF. 3. Stage IA, IB, IIA, IIB, or II MF: T1-T4 with measurable lesions 4. Previously treatment with at least one standard therapy used to treat Stage IA, IB, IIA, IIB, or III MF. 5. Measurable sk...
WP1220 is being developed for the treatment of cutaneous T-cell lymphoma, including mycosis fungoides, a form of skin lymphoma. It is a small molecule therapy that is applied as a topical treatment for skin lesions in adult patients. It is currently investigational and has not been approved for commercial use.
WP1220 targets p-STAT3, a protein involved in signaling pathways that drive the growth and survival of lymphoma cells. By inhibiting p-STAT3, the drug aims to interfere with the signaling that supports cutaneous T-cell lymphoma. This targeted approach is intended to act on the disease at the molecular level.
WP1220 is being developed by Moleculin Biotech, Inc., a clinical-stage pharmaceutical company. The company trades on the Nasdaq under the ticker symbol MBRX. Moleculin is focused on developing therapies for cancer and viral diseases, and WP1220 is one of its pipeline candidates in dermatology.
WP1220 is in Phase 1 clinical development. It has completed one Phase 1 trial, and no active trials are currently listed. As an investigational drug, it has not received FDA approval and remains in the early stages of clinical testing for cutaneous T-cell lymphoma.
WP1220 has been studied in one completed Phase 1 trial, NCT04702503, titled Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL). The trial enrolled five adult participants in Poland and was an uncontrolled, open-label study. No other clinical trials are currently listed for WP1220.